Hormone Therapy Less Risky for Menopausal Women than Assumed: New Study

Is hormone replacement therapy (HRT) worth the risks associated with it? Do its benefits of treating menopause symptoms outweigh the risks? These are the crucial questions right on the top of the minds of women looking to opt for HRT to treat osteoporosis, vaginal dryness, hot flashes, and the like. However, a new research published Tuesday in The Journal of the American Medical Association (JAMA) has a good news for menopausal women. JoAnn E. Manson, a lead author of the study, former North American Menopause Society (NAMS) president, and Harvard Medical School professor, has said hormone therapy had no association with all-cause mortality during the treatment and long-term follow-ups of the trials conducted.

Manson has also said that the findings of the new analysis should give a reassurance of hormone therapy being reasonable for symptomatic women in generally good health while in early menopause.

Menopausal Women and Doctors Reassured about Hormone Therapy

The Women’s Health Initiative hormone therapy trials are part of a randomized study that involved 27, 347 women who took hormone medicine while others were given a placebo. The trials have evaluated the risks and benefits of menopause hormone therapy taken by mainly healthy postmenopausal women to prevent chronic diseases. They tested estrogen plus progestin and estrogen alone–the most common sorts of hormone therapy.

The postmenopausal participants were 63 years old on an average at enrollment. The effect of treatment was explored between five to seven years along with 18 years of collective follow-up. The trials then explained how mortality rate was affected by hormone therapy. Alzheimer’s disease and other dementia deaths were considerably lower in participants who were given estrogen-alone than those given a placebo during the follow-up of 18 years.

NAMS director, Joann Pinkerton has said that the group does not recommend restricting hormone therapy to the shortest duration or lowest dose but finding the most suitable one for each woman. Pinkerton further said that there are fresher treatments available with potentially low risk of stroke or blood clots, such as transdermal patches.

Author: Rohit Bhisey

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business.

Leave a Reply